The edition · Psychiatry
The symptoms that do not move, and the mood stabiliser that does
Collaborative care shifts most of depression but not suicidality; partners resemble each other more than anyone assumed; and lithium and valproate come out level on suicide risk.
The edition in brief
A secondary analysis of the eIMPACT trial takes apart what collaborative care for depression actually does at the level of individual symptoms in 216 socioeconomically diverse primary care patients. It beat usual care on 15 of 20 checklist items and 7 of 9 PHQ-9 items, with moderate-to-large improvements in hopelessness, depressed mood, worthlessness, sleep and fatigue. It showed no advantage for suicidality, loneliness, sexual dysfunction, appetite change or psychomotor symptoms — the domains a falling total score hides. An FDA Class III recall covers 2 mg buprenorphine sublingual tablets from one American packager for a label mix-up. It is a labelling defect rather than a safety finding about the drug, but on a controlled substance where the dose on the strip is the whole instruction, it is worth checking stock against. Danish registry data on 4.2 million residents quantifies how much partners resemble each other psychiatrically: an overall correlation of 0.28, rising to 0.38 for schizophrenia. Modelling suggests this inflates the family-based heritability of psychiatric disorder by 12.5% and prevalence by 1.8% — which means part of what looks like inherited risk is the structure of who partners with whom. A pilot randomised trial of an Urdu-adapted transdiagnostic CBT protocol in Pakistan reports high feasibility and large preliminary effect sizes, with the caveats a waitlist-controlled pilot of 51 people carries. The edition closes on a Hong Kong cohort of 6,935 patients with bipolar disorder plus a network meta-analysis: lithium and valproate did not differ on suicide risk, while both beat no treatment.
Collaborative care moves most of depression — but not suicidality
Track suicidality, loneliness, sexual dysfunction, appetite and psychomotor symptoms separately from the total score — collaborative care did not shift them.
FDA Class III recall: buprenorphine 2 mg sublingual tablets, label mix-up
Check buprenorphine 2 mg stock from the named packager against the label; this changes dispensing checks, not prescribing.
Partners resemble each other psychiatrically, and it inflates what we call heritability
Ask about both parents' mental health, not just the patient's — partner correlation of 0.28 means one history does not stand in for the other.
A transdiagnostic CBT protocol, adapted and delivered in Urdu
Treat this as evidence that a culturally adapted transdiagnostic protocol can be delivered and completed in a low-resource South Asian setting — not yet as evidence of how well it works.
The lithium conversation that has to happen more than once
Repeat lithium sick-day and interaction counselling at every review — the patient who heard it once at initiation heard it at the worst possible moment.
Lithium and valproate come out level on suicide risk — so choose on everything else
Pick between lithium and valproate on renal function, pregnancy potential, monitoring and tolerability — not on a suicide-prevention advantage this analysis could not find.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free